You are invited to submit abstract presentations for review and selection for The Late-Breaking Research Program at the 2021 Annual Meeting, San Francisco, Calif., March 19-23.

The presentations will highlight the latest ground-breaking observations in dermatology and will be thematically organized into five categories - (i) clinical trials, (ii) clinical studies including those involving pediatric populations, (iii) procedural studies including Mohs/laser/cosmetic dermatology (iv) cutaneous oncology, basic science and dermatopathology and (v) technology/AI. Researchers are invited to submit abstracts describing their most recent results and the top scoring studies will be invited to discuss their findings in a brief oral presentation.

**New therapies will be given top priority**, particularly data from pivotal trials of unapproved drugs or unapproved indications. In addition, novel results that could be practice changing will also be given top consideration. **Case reports are not appropriate for this session and should be directed to Gross/Microscopic session.**

**Abstracts must be submitted by 11:59 PM Central Time on December 9, 2020.** After this date/time, the submission site will close automatically, and we will no longer be able to accept submissions. There will be **no exceptions** to this policy.

**QUALIFICATIONS**

All members of the Academy, residents, research fellows, and industry researchers are invited to submit their original research for review and selection. Non-member physicians and guests from outside the United States are also welcomed to submit abstracts provided the submissions are in English.

By submitting your abstract, you agree to present the abstract as an oral abstract presentation at the Annual Meeting. If your submission is accepted, you will be required to register for the Annual Meeting and pay the appropriate registration in order to present at the meeting. Non-member physicians who would like to participate will be required to register for the Annual Meeting as a non-member and pay the non-member fee.

**PRESENTATIONS**

All submissions will be reviewed by a team of expert reviewers and the top abstracts selected will reflect the best research from all aspects of dermatological science. Industry researchers may not provide product recommendations during their presentations. **Abstract submissions are limited to 250 words.**

- The final session schedule will depend on the number and nature of all accepted presentations.
- Specific presentation date and time requests cannot be guaranteed.
- Once a specific date/time is selected, you will be unable to reschedule.

Photos may be included in your presentation in the event your abstract is selected for one of the forums. **Photos WILL NOT be accepted during the submission process.**
The Late-Breaking Research Program
2021 Abstract Submission Guidelines and Procedures

All submitted abstract content will be embargoed until the first day of the AAD meeting at which time the abstracts will be posted online. However, the title and authors of the abstracts will be listed in the online searchable program for audience interest leading up to the start of the meeting.

GRADING OF ABSTRACTS
Abstracts submitted will be reviewed and graded via a blind review process. No identifiable information (e.g. institution names) is included in the review process. Abstracts should clearly identify the background, approach, results, innovation, and relevance of their research to dermatology.
Priority will be given to new therapies (particularly data from pivotal trials of unapproved drugs or unapproved indications), large epidemiological or genetic studies that shed light on disease risk, biomarker or molecular studies that have translational impact and basic science analyses that offer insight into disease mechanism.

When submitting your abstracts, it should be organized with the following information:
- Background
- Type of Study (e.g., case/control study, phase III trial, etc)
- Methods
- Results (include p values and statistical test if appropriate). Abstracts will be judged only on results provided in the submission.
  - Promissory data are not acceptable (e.g. “final results will be presented at the meeting”) and will be withdrawn from the program without notice.
- Conclusion

References should be submitted in the reference section of the online submission form and are not counted in the word count.

ELIGIBILITY REQUIREMENTS
1. All members of the Academy are invited to submit abstracts for review and selection.
2. Non-members and guests from outside the United States are welcome to submit abstracts provided they are submitted in English.
3. The Academy encourages medical students, residents, and fellows to present new material at the Annual Meeting.
4. Applications must be submitted online. Incomplete, faxed, or late entries will not be accepted.
5. General guidelines for content
   a. Clinical Trials: first-in-class early phase studies and large phase II/III pivotal studies. Biomarker studies are eligible if these are not exploratory in nature and if these point to improved therapeutic choice based on efficacy or safety
   b. Clinical research/pediatric studies: Substantial case series, large case/control studies with appropriate statistics; small therapeutic trials in the pediatric population. Large prospective trials with children may be submitted to the Clinical
The Late-Breaking Research Program

2021 Abstract Submission Guidelines and Procedures

Trial session. Cancer epidemiology studies may also be submitted to the Cutaneous Oncology/Basic Science/Dermatopathology session.

c. **Procedural/cosmetic dermatology:** advances in Mohs micrographic surgery; clinical trials of cosmetic devices (including lasers) or medications or combinations thereof; clinical research into cosmetic disorders.

d. **Cutaneous Oncology/Basic Science/Dermatopathology:** epidemiological studies that help define skin cancer risk or causation, small therapeutic trials in skin malignancies, biomarker studies in all aspects of dermatology, basic science studies about skin disease mechanism, novel genomic analyses of pathology tissue, novel diagnostics (e.g. molecular) in dermatopathology.

e. **Technology/Artificial Intelligence/Healthcare systems:** studies which deploy technology to fill a clinical gap or which improve healthcare delivery, testing of novel devices in humans or clinical settings, performance of innovative software including mobile technology and game changing AI systems.

6. If you submit the same abstract to multiple abstract programs and your abstract is accepted to more than one of the programs, you will be required to choose one program in which to present. The abstract will be withdrawn from the other program(s).
   a. The author is responsible for contacting the AAD to confirm the program in which they will be participating via email to abstracts@aad.org.

7. By submitting the abstract, the Primary Author listed on the initial submission agrees to present the abstract as an oral presentation at the Annual Meeting.
   a. **DO NOT** submit an abstract for consideration if you know you cannot attend the meeting.
   b. It is the responsibility of the primary author to inform the AAD in the event that he/she cannot present and provide an alternate presenter if possible.
   c. **Only a co-author,** listed on the original submission will be accepted as an alternate presenter. MAKE SURE ALL AUTHORS ARE INCLUDED IN THE ORIGINAL SUBMISSION, as you are unable to edit the submission after the deadline.
   d. There is a limit of 10 authors per submission plus the Primary Author (11 total).
      i. **At least one author listed on the submission should be a current AAD member.**
      ii. **Authors should be entered in the order that they will be published.** This information cannot be changed once the abstract is submitted.

8. If your submission is accepted, you will be required to register to attend the meeting and pay the appropriate registration.

9. Applicants are required to disclose any financial relationships with commercial companies. In the event an author has no financial relationships, they must add a comment that states, ‘Author has no relevant financial relationships to disclose’.

What is **Not** Eligible for Submission:

1. An abstract is ineligible for consideration if it reports work that has been published or was accepted for publication as a manuscript that will be published prior to the scheduled presentation time at the Annual Meeting (e.g., full-length article, brief report, case report, concise communication or letter to the editor, in press articles, etc.)
   o Manuscripts under revision are eligible.
2. Applicants should not submit abstracts that include material that has already been presented at previous Academy meetings or other scientific meetings within the United States or abroad.
3. The same study should not be submitted as multiple abstracts. Abstracts that appear as more than one version of a single study will be withdrawn without notice.

4. Submissions will be withdrawn without notice if they utilize any materials/slides that have been created by a commercial entity and include promotional messages and/or corporate logos. QR codes are acceptable in the final presentations as long as they do not link to any promotional messaging or logos.

Email notifications will be sent to the primary author’s email address by the end of January. Questions regarding your submission should be directed to abstracts@aad.org.